nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftriaxone—SLC22A11—Methotrexate—lymphatic system cancer	0.187	0.429	CbGbCtD
Ceftriaxone—SLC22A8—Methotrexate—lymphatic system cancer	0.109	0.249	CbGbCtD
Ceftriaxone—SLC22A6—Methotrexate—lymphatic system cancer	0.0759	0.174	CbGbCtD
Ceftriaxone—ALB—Methotrexate—lymphatic system cancer	0.0647	0.148	CbGbCtD
Ceftriaxone—Candida infection—Carmustine—lymphatic system cancer	0.0027	0.0048	CcSEcCtD
Ceftriaxone—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00267	0.00474	CcSEcCtD
Ceftriaxone—Neutropenia—Fludarabine—lymphatic system cancer	0.00259	0.0046	CcSEcCtD
Ceftriaxone—Haemoglobin—Teniposide—lymphatic system cancer	0.00254	0.00451	CcSEcCtD
Ceftriaxone—Haemorrhage—Teniposide—lymphatic system cancer	0.00252	0.00448	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00245	0.00435	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00243	0.00432	CcSEcCtD
Ceftriaxone—Renal failure—Fludarabine—lymphatic system cancer	0.00243	0.00432	CcSEcCtD
Ceftriaxone—Infection—Mechlorethamine—lymphatic system cancer	0.00242	0.00429	CcSEcCtD
Ceftriaxone—Stomatitis—Fludarabine—lymphatic system cancer	0.00241	0.00428	CcSEcCtD
Ceftriaxone—Phlebitis—Carmustine—lymphatic system cancer	0.00238	0.00423	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00238	0.00423	CcSEcCtD
Ceftriaxone—Thrombophlebitis—Carmustine—lymphatic system cancer	0.00237	0.00421	CcSEcCtD
Ceftriaxone—Haematuria—Fludarabine—lymphatic system cancer	0.00236	0.00419	CcSEcCtD
Ceftriaxone—Flushing—Teniposide—lymphatic system cancer	0.00234	0.00416	CcSEcCtD
Ceftriaxone—Epistaxis—Fludarabine—lymphatic system cancer	0.00233	0.00414	CcSEcCtD
Ceftriaxone—Chills—Teniposide—lymphatic system cancer	0.00226	0.00402	CcSEcCtD
Ceftriaxone—Haemoglobin—Fludarabine—lymphatic system cancer	0.00223	0.00396	CcSEcCtD
Ceftriaxone—Haemorrhage—Fludarabine—lymphatic system cancer	0.00222	0.00394	CcSEcCtD
Ceftriaxone—Phlebitis—Mitoxantrone—lymphatic system cancer	0.00221	0.00393	CcSEcCtD
Ceftriaxone—Erythema multiforme—Fludarabine—lymphatic system cancer	0.0021	0.00373	CcSEcCtD
Ceftriaxone—Anaemia—Teniposide—lymphatic system cancer	0.00203	0.00361	CcSEcCtD
Ceftriaxone—Agitation—Teniposide—lymphatic system cancer	0.00202	0.00359	CcSEcCtD
Ceftriaxone—Bronchospasm—Bleomycin—lymphatic system cancer	0.002	0.00355	CcSEcCtD
Ceftriaxone—Chills—Fludarabine—lymphatic system cancer	0.00199	0.00354	CcSEcCtD
Ceftriaxone—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00197	0.0035	CcSEcCtD
Ceftriaxone—Leukopenia—Teniposide—lymphatic system cancer	0.00197	0.00349	CcSEcCtD
Ceftriaxone—Ataxia—Carmustine—lymphatic system cancer	0.00193	0.00343	CcSEcCtD
Ceftriaxone—Ataxia—Vincristine—lymphatic system cancer	0.00184	0.00327	CcSEcCtD
Ceftriaxone—Oedema—Teniposide—lymphatic system cancer	0.00179	0.00319	CcSEcCtD
Ceftriaxone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00179	0.00318	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00179	0.00318	CcSEcCtD
Ceftriaxone—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00179	0.00318	CcSEcCtD
Ceftriaxone—Anaemia—Fludarabine—lymphatic system cancer	0.00178	0.00317	CcSEcCtD
Ceftriaxone—Infection—Teniposide—lymphatic system cancer	0.00178	0.00316	CcSEcCtD
Ceftriaxone—Agitation—Fludarabine—lymphatic system cancer	0.00177	0.00315	CcSEcCtD
Ceftriaxone—Stomatitis—Bleomycin—lymphatic system cancer	0.00177	0.00314	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00176	0.00313	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00176	0.00312	CcSEcCtD
Ceftriaxone—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00174	0.0031	CcSEcCtD
Ceftriaxone—Malaise—Fludarabine—lymphatic system cancer	0.00174	0.00309	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00173	0.00308	CcSEcCtD
Ceftriaxone—Leukopenia—Fludarabine—lymphatic system cancer	0.00173	0.00307	CcSEcCtD
Ceftriaxone—Haematuria—Bleomycin—lymphatic system cancer	0.00173	0.00307	CcSEcCtD
Ceftriaxone—Pruritus—Mechlorethamine—lymphatic system cancer	0.00172	0.00306	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00172	0.00305	CcSEcCtD
Ceftriaxone—Fungal infection—Methotrexate—lymphatic system cancer	0.0017	0.00301	CcSEcCtD
Ceftriaxone—Convulsion—Fludarabine—lymphatic system cancer	0.00167	0.00297	CcSEcCtD
Ceftriaxone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00166	0.00296	CcSEcCtD
Ceftriaxone—Neutropenia—Carmustine—lymphatic system cancer	0.00166	0.00295	CcSEcCtD
Ceftriaxone—Haemoglobin—Bleomycin—lymphatic system cancer	0.00163	0.0029	CcSEcCtD
Ceftriaxone—Haemorrhage—Bleomycin—lymphatic system cancer	0.00163	0.00289	CcSEcCtD
Ceftriaxone—Discomfort—Fludarabine—lymphatic system cancer	0.00162	0.00289	CcSEcCtD
Ceftriaxone—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00161	0.00285	CcSEcCtD
Ceftriaxone—Neutropenia—Vincristine—lymphatic system cancer	0.00158	0.00281	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00158	0.0028	CcSEcCtD
Ceftriaxone—Oedema—Fludarabine—lymphatic system cancer	0.00158	0.0028	CcSEcCtD
Ceftriaxone—Infection—Fludarabine—lymphatic system cancer	0.00157	0.00278	CcSEcCtD
Ceftriaxone—Renal failure—Carmustine—lymphatic system cancer	0.00155	0.00276	CcSEcCtD
Ceftriaxone—Vomiting—Mechlorethamine—lymphatic system cancer	0.00155	0.00275	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00154	0.00274	CcSEcCtD
Ceftriaxone—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00154	0.00274	CcSEcCtD
Ceftriaxone—Stomatitis—Carmustine—lymphatic system cancer	0.00154	0.00274	CcSEcCtD
Ceftriaxone—Rash—Mechlorethamine—lymphatic system cancer	0.00153	0.00272	CcSEcCtD
Ceftriaxone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00153	0.00272	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00152	0.00271	CcSEcCtD
Ceftriaxone—Flushing—Bleomycin—lymphatic system cancer	0.00151	0.00268	CcSEcCtD
Ceftriaxone—Proteinuria—Methotrexate—lymphatic system cancer	0.00149	0.00265	CcSEcCtD
Ceftriaxone—Feeling abnormal—Teniposide—lymphatic system cancer	0.00148	0.00263	CcSEcCtD
Ceftriaxone—Stomatitis—Vincristine—lymphatic system cancer	0.00147	0.00261	CcSEcCtD
Ceftriaxone—Protein urine present—Methotrexate—lymphatic system cancer	0.00147	0.00261	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00147	0.0026	CcSEcCtD
Ceftriaxone—Chills—Bleomycin—lymphatic system cancer	0.00146	0.00259	CcSEcCtD
Ceftriaxone—Renal failure—Mitoxantrone—lymphatic system cancer	0.00145	0.00257	CcSEcCtD
Ceftriaxone—Nausea—Mechlorethamine—lymphatic system cancer	0.00144	0.00257	CcSEcCtD
Ceftriaxone—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00143	0.00255	CcSEcCtD
Ceftriaxone—Jaundice—Mitoxantrone—lymphatic system cancer	0.00143	0.00255	CcSEcCtD
Ceftriaxone—Haemoglobin—Carmustine—lymphatic system cancer	0.00143	0.00253	CcSEcCtD
Ceftriaxone—Urticaria—Teniposide—lymphatic system cancer	0.00142	0.00253	CcSEcCtD
Ceftriaxone—Glossitis—Methotrexate—lymphatic system cancer	0.00142	0.00252	CcSEcCtD
Ceftriaxone—Oliguria—Methotrexate—lymphatic system cancer	0.00142	0.00252	CcSEcCtD
Ceftriaxone—Haemorrhage—Carmustine—lymphatic system cancer	0.00142	0.00252	CcSEcCtD
Ceftriaxone—Abdominal pain—Teniposide—lymphatic system cancer	0.00142	0.00252	CcSEcCtD
Ceftriaxone—Body temperature increased—Teniposide—lymphatic system cancer	0.00142	0.00252	CcSEcCtD
Ceftriaxone—Paraesthesia—Fludarabine—lymphatic system cancer	0.00141	0.00251	CcSEcCtD
Ceftriaxone—Haematuria—Mitoxantrone—lymphatic system cancer	0.0014	0.00249	CcSEcCtD
Ceftriaxone—Dyspepsia—Fludarabine—lymphatic system cancer	0.00139	0.00246	CcSEcCtD
Ceftriaxone—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00137	0.00244	CcSEcCtD
Ceftriaxone—Pain—Fludarabine—lymphatic system cancer	0.00135	0.00239	CcSEcCtD
Ceftriaxone—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00133	0.00236	CcSEcCtD
Ceftriaxone—Hypersensitivity—Teniposide—lymphatic system cancer	0.00132	0.00235	CcSEcCtD
Ceftriaxone—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00132	0.00234	CcSEcCtD
Ceftriaxone—Flushing—Carmustine—lymphatic system cancer	0.00132	0.00234	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00131	0.00233	CcSEcCtD
Ceftriaxone—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00131	0.00233	CcSEcCtD
Ceftriaxone—Anaemia—Bleomycin—lymphatic system cancer	0.00131	0.00232	CcSEcCtD
Ceftriaxone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0013	0.00231	CcSEcCtD
Ceftriaxone—Malaise—Bleomycin—lymphatic system cancer	0.00128	0.00227	CcSEcCtD
Ceftriaxone—Pruritus—Teniposide—lymphatic system cancer	0.00127	0.00225	CcSEcCtD
Ceftriaxone—Leukopenia—Bleomycin—lymphatic system cancer	0.00127	0.00225	CcSEcCtD
Ceftriaxone—Body temperature increased—Fludarabine—lymphatic system cancer	0.00125	0.00221	CcSEcCtD
Ceftriaxone—Vaginal infection—Methotrexate—lymphatic system cancer	0.00124	0.0022	CcSEcCtD
Ceftriaxone—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00123	0.00218	CcSEcCtD
Ceftriaxone—Diarrhoea—Teniposide—lymphatic system cancer	0.00123	0.00218	CcSEcCtD
Ceftriaxone—Discomfort—Bleomycin—lymphatic system cancer	0.00119	0.00212	CcSEcCtD
Ceftriaxone—Chills—Mitoxantrone—lymphatic system cancer	0.00118	0.0021	CcSEcCtD
Ceftriaxone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00116	0.00206	CcSEcCtD
Ceftriaxone—Oedema—Bleomycin—lymphatic system cancer	0.00116	0.00205	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00116	0.00205	CcSEcCtD
Ceftriaxone—Infection—Bleomycin—lymphatic system cancer	0.00115	0.00204	CcSEcCtD
Ceftriaxone—Anaemia—Carmustine—lymphatic system cancer	0.00114	0.00203	CcSEcCtD
Ceftriaxone—Vomiting—Teniposide—lymphatic system cancer	0.00114	0.00203	CcSEcCtD
Ceftriaxone—Agitation—Carmustine—lymphatic system cancer	0.00114	0.00202	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00113	0.00201	CcSEcCtD
Ceftriaxone—Rash—Teniposide—lymphatic system cancer	0.00113	0.00201	CcSEcCtD
Ceftriaxone—Dermatitis—Teniposide—lymphatic system cancer	0.00113	0.00201	CcSEcCtD
Ceftriaxone—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00113	0.002	CcSEcCtD
Ceftriaxone—Headache—Teniposide—lymphatic system cancer	0.00112	0.002	CcSEcCtD
Ceftriaxone—Pruritus—Fludarabine—lymphatic system cancer	0.00111	0.00198	CcSEcCtD
Ceftriaxone—Leukopenia—Carmustine—lymphatic system cancer	0.00111	0.00197	CcSEcCtD
Ceftriaxone—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.0011	0.00195	CcSEcCtD
Ceftriaxone—Anaemia—Vincristine—lymphatic system cancer	0.00109	0.00194	CcSEcCtD
Ceftriaxone—Agitation—Vincristine—lymphatic system cancer	0.00108	0.00193	CcSEcCtD
Ceftriaxone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00108	0.00192	CcSEcCtD
Ceftriaxone—Convulsion—Carmustine—lymphatic system cancer	0.00107	0.0019	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00107	0.00189	CcSEcCtD
Ceftriaxone—Nausea—Teniposide—lymphatic system cancer	0.00107	0.00189	CcSEcCtD
Ceftriaxone—Anaemia—Mitoxantrone—lymphatic system cancer	0.00106	0.00189	CcSEcCtD
Ceftriaxone—Leukopenia—Vincristine—lymphatic system cancer	0.00106	0.00188	CcSEcCtD
Ceftriaxone—Paraesthesia—Bleomycin—lymphatic system cancer	0.00104	0.00184	CcSEcCtD
Ceftriaxone—Malaise—Mitoxantrone—lymphatic system cancer	0.00104	0.00184	CcSEcCtD
Ceftriaxone—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00103	0.00183	CcSEcCtD
Ceftriaxone—Convulsion—Vincristine—lymphatic system cancer	0.00102	0.00182	CcSEcCtD
Ceftriaxone—Oedema—Carmustine—lymphatic system cancer	0.00101	0.00179	CcSEcCtD
Ceftriaxone—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00101	0.00179	CcSEcCtD
Ceftriaxone—Infection—Carmustine—lymphatic system cancer	0.001	0.00178	CcSEcCtD
Ceftriaxone—Vomiting—Fludarabine—lymphatic system cancer	0.001	0.00178	CcSEcCtD
Ceftriaxone—Convulsion—Mitoxantrone—lymphatic system cancer	0.000995	0.00177	CcSEcCtD
Ceftriaxone—Rash—Fludarabine—lymphatic system cancer	0.000994	0.00177	CcSEcCtD
Ceftriaxone—Dermatitis—Fludarabine—lymphatic system cancer	0.000993	0.00176	CcSEcCtD
Ceftriaxone—Pain—Bleomycin—lymphatic system cancer	0.000988	0.00176	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000987	0.00175	CcSEcCtD
Ceftriaxone—Headache—Fludarabine—lymphatic system cancer	0.000987	0.00175	CcSEcCtD
Ceftriaxone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000982	0.00174	CcSEcCtD
Ceftriaxone—Discomfort—Mitoxantrone—lymphatic system cancer	0.000966	0.00172	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000963	0.00171	CcSEcCtD
Ceftriaxone—Oedema—Vincristine—lymphatic system cancer	0.000963	0.00171	CcSEcCtD
Ceftriaxone—Infection—Vincristine—lymphatic system cancer	0.000956	0.0017	CcSEcCtD
Ceftriaxone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000952	0.00169	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000943	0.00167	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000938	0.00167	CcSEcCtD
Ceftriaxone—Oedema—Mitoxantrone—lymphatic system cancer	0.000938	0.00167	CcSEcCtD
Ceftriaxone—Nausea—Fludarabine—lymphatic system cancer	0.000936	0.00166	CcSEcCtD
Ceftriaxone—Infection—Mitoxantrone—lymphatic system cancer	0.000931	0.00165	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000931	0.00165	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000918	0.00163	CcSEcCtD
Ceftriaxone—Urticaria—Bleomycin—lymphatic system cancer	0.000918	0.00163	CcSEcCtD
Ceftriaxone—Body temperature increased—Bleomycin—lymphatic system cancer	0.000913	0.00162	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000906	0.00161	CcSEcCtD
Ceftriaxone—Paraesthesia—Carmustine—lymphatic system cancer	0.000906	0.00161	CcSEcCtD
Ceftriaxone—Ataxia—Methotrexate—lymphatic system cancer	0.000894	0.00159	CcSEcCtD
Ceftriaxone—Paraesthesia—Vincristine—lymphatic system cancer	0.000864	0.00154	CcSEcCtD
Ceftriaxone—Pain—Carmustine—lymphatic system cancer	0.000862	0.00153	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000856	0.00152	CcSEcCtD
Ceftriaxone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000851	0.00151	CcSEcCtD
Ceftriaxone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000842	0.0015	CcSEcCtD
Ceftriaxone—Feeling abnormal—Carmustine—lymphatic system cancer	0.000831	0.00148	CcSEcCtD
Ceftriaxone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000825	0.00147	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000825	0.00147	CcSEcCtD
Ceftriaxone—Pain—Vincristine—lymphatic system cancer	0.000823	0.00146	CcSEcCtD
Ceftriaxone—Pruritus—Bleomycin—lymphatic system cancer	0.000817	0.00145	CcSEcCtD
Ceftriaxone—Eosinophilia—Methotrexate—lymphatic system cancer	0.000813	0.00145	CcSEcCtD
Ceftriaxone—Pancreatitis—Methotrexate—lymphatic system cancer	0.000805	0.00143	CcSEcCtD
Ceftriaxone—Pain—Mitoxantrone—lymphatic system cancer	0.000802	0.00142	CcSEcCtD
Ceftriaxone—Abdominal pain—Carmustine—lymphatic system cancer	0.000797	0.00142	CcSEcCtD
Ceftriaxone—Body temperature increased—Carmustine—lymphatic system cancer	0.000797	0.00142	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000787	0.0014	CcSEcCtD
Ceftriaxone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000773	0.00137	CcSEcCtD
Ceftriaxone—Neutropenia—Methotrexate—lymphatic system cancer	0.000768	0.00136	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000767	0.00136	CcSEcCtD
Ceftriaxone—Abdominal pain—Vincristine—lymphatic system cancer	0.000761	0.00135	CcSEcCtD
Ceftriaxone—Body temperature increased—Vincristine—lymphatic system cancer	0.000761	0.00135	CcSEcCtD
Ceftriaxone—Urticaria—Mitoxantrone—lymphatic system cancer	0.000745	0.00132	CcSEcCtD
Ceftriaxone—Hypersensitivity—Carmustine—lymphatic system cancer	0.000743	0.00132	CcSEcCtD
Ceftriaxone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000741	0.00132	CcSEcCtD
Ceftriaxone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000741	0.00132	CcSEcCtD
Ceftriaxone—Vomiting—Bleomycin—lymphatic system cancer	0.000735	0.00131	CcSEcCtD
Ceftriaxone—Rash—Bleomycin—lymphatic system cancer	0.000728	0.00129	CcSEcCtD
Ceftriaxone—Dermatitis—Bleomycin—lymphatic system cancer	0.000728	0.00129	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000726	0.00129	CcSEcCtD
Ceftriaxone—Renal failure—Methotrexate—lymphatic system cancer	0.00072	0.00128	CcSEcCtD
Ceftriaxone—Stomatitis—Methotrexate—lymphatic system cancer	0.000714	0.00127	CcSEcCtD
Ceftriaxone—Hypersensitivity—Vincristine—lymphatic system cancer	0.000709	0.00126	CcSEcCtD
Ceftriaxone—Haematuria—Methotrexate—lymphatic system cancer	0.000698	0.00124	CcSEcCtD
Ceftriaxone—Epistaxis—Methotrexate—lymphatic system cancer	0.000691	0.00123	CcSEcCtD
Ceftriaxone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000691	0.00123	CcSEcCtD
Ceftriaxone—Diarrhoea—Carmustine—lymphatic system cancer	0.00069	0.00123	CcSEcCtD
Ceftriaxone—Nausea—Bleomycin—lymphatic system cancer	0.000686	0.00122	CcSEcCtD
Ceftriaxone—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000684	0.00121	CcSEcCtD
Ceftriaxone—Dizziness—Carmustine—lymphatic system cancer	0.000667	0.00118	CcSEcCtD
Ceftriaxone—Haemoglobin—Methotrexate—lymphatic system cancer	0.000661	0.00117	CcSEcCtD
Ceftriaxone—Diarrhoea—Vincristine—lymphatic system cancer	0.000659	0.00117	CcSEcCtD
Ceftriaxone—Haemorrhage—Methotrexate—lymphatic system cancer	0.000658	0.00117	CcSEcCtD
Ceftriaxone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000642	0.00114	CcSEcCtD
Ceftriaxone—Vomiting—Carmustine—lymphatic system cancer	0.000641	0.00114	CcSEcCtD
Ceftriaxone—Dizziness—Vincristine—lymphatic system cancer	0.000637	0.00113	CcSEcCtD
Ceftriaxone—Rash—Carmustine—lymphatic system cancer	0.000636	0.00113	CcSEcCtD
Ceftriaxone—Dermatitis—Carmustine—lymphatic system cancer	0.000635	0.00113	CcSEcCtD
Ceftriaxone—Headache—Carmustine—lymphatic system cancer	0.000632	0.00112	CcSEcCtD
Ceftriaxone—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000622	0.0011	CcSEcCtD
Ceftriaxone—Vomiting—Vincristine—lymphatic system cancer	0.000612	0.00109	CcSEcCtD
Ceftriaxone—Rash—Vincristine—lymphatic system cancer	0.000607	0.00108	CcSEcCtD
Ceftriaxone—Dermatitis—Vincristine—lymphatic system cancer	0.000606	0.00108	CcSEcCtD
Ceftriaxone—Headache—Vincristine—lymphatic system cancer	0.000603	0.00107	CcSEcCtD
Ceftriaxone—Nausea—Carmustine—lymphatic system cancer	0.000599	0.00106	CcSEcCtD
Ceftriaxone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000596	0.00106	CcSEcCtD
Ceftriaxone—Rash—Mitoxantrone—lymphatic system cancer	0.000591	0.00105	CcSEcCtD
Ceftriaxone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000591	0.00105	CcSEcCtD
Ceftriaxone—Chills—Methotrexate—lymphatic system cancer	0.00059	0.00105	CcSEcCtD
Ceftriaxone—Headache—Mitoxantrone—lymphatic system cancer	0.000587	0.00104	CcSEcCtD
Ceftriaxone—Nausea—Vincristine—lymphatic system cancer	0.000572	0.00102	CcSEcCtD
Ceftriaxone—Dysgeusia—Methotrexate—lymphatic system cancer	0.000561	0.000996	CcSEcCtD
Ceftriaxone—Nausea—Mitoxantrone—lymphatic system cancer	0.000557	0.00099	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000531	0.000944	CcSEcCtD
Ceftriaxone—Anaemia—Methotrexate—lymphatic system cancer	0.000529	0.00094	CcSEcCtD
Ceftriaxone—Malaise—Methotrexate—lymphatic system cancer	0.000516	0.000917	CcSEcCtD
Ceftriaxone—Leukopenia—Methotrexate—lymphatic system cancer	0.000512	0.00091	CcSEcCtD
Ceftriaxone—Convulsion—Methotrexate—lymphatic system cancer	0.000496	0.000881	CcSEcCtD
Ceftriaxone—Discomfort—Methotrexate—lymphatic system cancer	0.000481	0.000855	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000467	0.00083	CcSEcCtD
Ceftriaxone—Infection—Methotrexate—lymphatic system cancer	0.000464	0.000825	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000457	0.000813	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000452	0.000802	CcSEcCtD
Ceftriaxone—Paraesthesia—Methotrexate—lymphatic system cancer	0.000419	0.000745	CcSEcCtD
Ceftriaxone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000411	0.000731	CcSEcCtD
Ceftriaxone—Pain—Methotrexate—lymphatic system cancer	0.000399	0.00071	CcSEcCtD
Ceftriaxone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000385	0.000684	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000382	0.000679	CcSEcCtD
Ceftriaxone—Urticaria—Methotrexate—lymphatic system cancer	0.000371	0.000659	CcSEcCtD
Ceftriaxone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000369	0.000656	CcSEcCtD
Ceftriaxone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000369	0.000656	CcSEcCtD
Ceftriaxone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000344	0.000612	CcSEcCtD
Ceftriaxone—Pruritus—Methotrexate—lymphatic system cancer	0.00033	0.000587	CcSEcCtD
Ceftriaxone—Diarrhoea—Methotrexate—lymphatic system cancer	0.00032	0.000568	CcSEcCtD
Ceftriaxone—Dizziness—Methotrexate—lymphatic system cancer	0.000309	0.000549	CcSEcCtD
Ceftriaxone—Vomiting—Methotrexate—lymphatic system cancer	0.000297	0.000528	CcSEcCtD
Ceftriaxone—Rash—Methotrexate—lymphatic system cancer	0.000295	0.000523	CcSEcCtD
Ceftriaxone—Dermatitis—Methotrexate—lymphatic system cancer	0.000294	0.000523	CcSEcCtD
Ceftriaxone—Headache—Methotrexate—lymphatic system cancer	0.000293	0.00052	CcSEcCtD
Ceftriaxone—Nausea—Methotrexate—lymphatic system cancer	0.000277	0.000493	CcSEcCtD
